Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 86 P313 | DOI: 10.1530/endoabs.86.P313

SFEBES2022 Poster Presentations Bone and Calcium (40 abstracts)

Bone Turnover Markers for Assessment of Anti-Resorptive Effect in Clinical Practice: A Good Idea Meets the Problem of Measurement Uncertainty

Gregory Kline 1,2 & Daniel Holmes 3


1University of Calgary, Calgary, Canada; 2Dr. David Hanley Osteoporosis Centre, Calgary, Canada; 3University of British Columbia, Vancouver, Canada


Background: Bone turnover markers (BTM) are potential measures for understanding the effect of antiresorptive medications upon osteoclast activity. As a dynamic marker of therapy effect, they could complement or replace DXA-BMD. The translation of population data on BTM changes with therapy to the individual patient is less established. Post-hoc trial data suggests a reduction in BTM of 40% may represent a target for defining appropriate response to therapy.

Aim: We modeled the clinical application of this target threshold in an individual patient setting where assay measurement uncertainty and biological variation are included.

Methods: Using C-telo-peptide (CTX), we constructed hypothetical scenarios of CTX measurement pre and post bisphosphonate therapy. Using typical CTX assay characteristics (analytical CV 5.0%) and published intra-individual CTX data for post-menopausal women (CVi 18.0%), we calculated the level of post-therapy CTX that must be seen on single repeat measure in order to be 95% confident that the observed result was ≥40% lower from baseline. Sensitivity analyses considered greater and lesser variations in the combined sources of variation.

Results: The one-tailed 95% reference change value for any detectable therapeutic decrease in CTX was 22% at the mid-point reference interval. However, to have 95% confidence of having achieved a reduction ≥ 40%, an observed CTX decrease of 56% is required. Even larger decreases are needed for scenarios of greater analytical or intra-individual variation.

Conclusions: Although population data may suggest a CTX decrease of 40% is commensurate with adequate therapeutic response to anti-resorptives, the application to an individual patient where measurement and natural variation are present is problematic. CTX decreases much greater than 40% are required in order to be certain of having achieved a 40% decrease. It is uncertain whether this is a legitimate change to be expected in most individual patients and therefore clinical application of this threshold is uncertain.

Volume 86

Society for Endocrinology BES 2022

Harrogate, United Kingdom
14 Nov 2022 - 16 Nov 2022

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.